These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10594328)

  • 1. Contrasting roles of leu(356) in the human CCK(1) receptor for antagonist SR 27897 and agonist SR 146131 binding.
    Gouldson P; Legoux P; Carillon C; Delpech B; Le Fur G; Ferrara P; Shire D
    Eur J Pharmacol; 1999 Nov; 383(3):339-46. PubMed ID: 10594328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor.
    Gouldson P; Legoux P; Carillon C; Delpech B; Le Fur G; Ferrara P; Shire D
    Eur J Pharmacol; 2000 Jul; 400(2-3):185-94. PubMed ID: 10988332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S.
    Gouldson P; Legoux P; Carillon C; Dumont X; Le Fur G; Ferrara P; Shire D
    Eur J Pharmacol; 2000 Feb; 389(2-3):115-24. PubMed ID: 10688974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full and partial agonist activity of C-terminal cholecystokinin peptides at the cloned human CCK-A receptor expressed in Chinese hamster ovary cells.
    Dunlop J; Zhang Y; Evans N
    Peptides; 1997; 18(6):865-8. PubMed ID: 9285936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
    J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
    Bignon E; Bachy A; Boigegrain R; Brodin R; Cottineau M; Gully D; Herbert JM; Keane P; Labie C; Molimard JC; Olliero D; Oury-Donat F; Petereau C; Prabonnaud V; Rockstroh MP; Schaeffer P; Servant O; Thurneyssen O; Soubrié P; Pascal M; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists.
    Bläker M; Ren Y; Gordon MC; Hsu JE; Beinborn M; Kopin AS
    Mol Pharmacol; 1998 Nov; 54(5):857-63. PubMed ID: 9804620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.
    Harper EA; Griffin EP; Shankley NP; Black JW
    Br J Pharmacol; 1999 Mar; 126(6):1496-503. PubMed ID: 10217545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists?
    Patel S; Chapman KL; Smith AJ; Bailey I; Freedman SB
    Regul Pept; 1996 Aug; 65(1):29-35. PubMed ID: 8876033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H]-SR 27897B: a selective probe for autoradiographic labelling of CCK-A receptors in the brain.
    Zajac JM; Gully D; Maffrand JP
    J Recept Signal Transduct Res; 1996; 16(1-2):93-113. PubMed ID: 8771533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
    Kennedy K; Gigoux V; Escrieut C; Maigret B; Martinez J; Moroder L; Fréhel D; Gully D; Vaysse N; Fourmy D
    J Biol Chem; 1997 Jan; 272(5):2920-6. PubMed ID: 9006937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179.
    Silvente Poirot S; Hadjiivanova C; Escrieut C; Dufresne M; Martinez J; Vaysse N; Fourmy D
    Eur J Biochem; 1993 Mar; 212(2):529-38. PubMed ID: 8444190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
    Gully D; Fréhel D; Marcy C; Spinazzé A; Lespy L; Neliat G; Maffrand JP; Le Fur G
    Eur J Pharmacol; 1993 Feb; 232(1):13-9. PubMed ID: 7681406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the CCK(A) receptor antagonists SR 27897B and PD140548 on baroreflex function in conscious rats.
    Bunting MW; Beart PM; Widdop RE
    Eur J Pharmacol; 1997 Oct; 337(1):35-9. PubMed ID: 9389378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of the effects of SR146131, a novel non-peptide CCK(1) receptor agonist, on IMR-32 human neuroblastoma cells.
    Schaeffer P; Nestor AL; Prabonnaud V; Bachy A; Laplace MC; Keane PE; Bignon E; Herbert JM
    Eur J Pharmacol; 2000 Jun; 397(2-3):303-10. PubMed ID: 10844128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of the putative devazepide binding site of the CCK(A) receptor.
    Smeets RL; IJzerman AP; Hermsen HP; Ophorst OJ; Van Emst-de Vries SE; De Pont JJ; Willems PH
    Eur J Pharmacol; 1997 Apr; 325(1):93-9. PubMed ID: 9151944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the extracellular domains of the cholecystokinin receptor in agonist binding.
    Silvente-Poirot S; Escrieut C; Wank SA
    Mol Pharmacol; 1998 Aug; 54(2):364-71. PubMed ID: 9687578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.
    Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP
    Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conserved cholecystokinin receptor transmembrane domain IV amino acids confer peptide affinity.
    Ren Y; Bläker M; Seshadri L; McBride EW; Beinborn M; Kopin AS
    J Mol Neurosci; 2003 Apr; 20(2):115-24. PubMed ID: 12794305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands.
    Kopin AS; McBride EW; Quinn SM; Kolakowski LF; Beinborn M
    J Biol Chem; 1995 Mar; 270(10):5019-23. PubMed ID: 7890609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.